Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Merkelbach-Bruse

P1.01-72 FIND Trial: A Phase II Study to Evaluate the Efficacy of the FGFR-Inhibitor Erdafitinib in FGFR-Mutated and -Translocated Squamous NSCLC

Journal of Thoracic Oncology

English

Related publications

A Phase I, Multicenter, Dose-Escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients With Advanced Solid Tumors Harboring FGFR Gene Alterations

Clinical Cancer Research

Cancer Research

Oncology

2019

English

Bcl‐2 Inhibitors Enhance FGFR Inhibitor‐induced Mitochondrial‐dependent Cell Death in FGFR 2 Mutant Endometrial Cancer

English

P1.01-54 a Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC

Journal of Thoracic Oncology

English

P1.01-38 a Phase II With a Lead-In Phase I Study to Examine Safety and Efficacy of Hydroxychloroquine and Gefitinib in Advanced NSCLC

Journal of Thoracic Oncology

English

Rogaratinib: A Potent and Selective Pan-FGFR Inhibitor With Broad Antitumor Activity in FGFR-overexpressing Preclinical Cancer Models

International Journal of Cancer

Cancer Research

Oncology

2019

English

First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors

English

Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC

Cancer Research

Oncology

2014

English

P1.01-66 Randomized Phase II Evaluating EGFR-TKI Associated With Anti-Estrogen in Women With Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial

Journal of Thoracic Oncology

English

Targeting FGFR Signaling in Cancer

Clinical Cancer Research

Cancer Research

Oncology

2015

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Merkelbach-Bruse

P1.01-72 FIND Trial: A Phase II Study to Evaluate the Efficacy of the FGFR-Inhibitor Erdafitinib in FGFR-Mutated and -Translocated Squamous NSCLC

Related publications

A Phase I, Multicenter, Dose-Escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients With Advanced Solid Tumors Harboring FGFR Gene Alterations

Bcl‐2 Inhibitors Enhance FGFR Inhibitor‐induced Mitochondrial‐dependent Cell Death in FGFR 2 Mutant Endometrial Cancer

P1.01-54 a Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC

P1.01-38 a Phase II With a Lead-In Phase I Study to Examine Safety and Efficacy of Hydroxychloroquine and Gefitinib in Advanced NSCLC

Rogaratinib: A Potent and Selective Pan-FGFR Inhibitor With Broad Antitumor Activity in FGFR-overexpressing Preclinical Cancer Models

First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors

Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC

P1.01-66 Randomized Phase II Evaluating EGFR-TKI Associated With Anti-Estrogen in Women With Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial

Targeting FGFR Signaling in Cancer